The mammalian target of rapamycin (mTOR) critically regulates several essential biological functions, such as cell growth, metabolism, survival, and immune response by forming two important complexes, namely, mTOR complex 1 (mTORC1) and complex 2 (mTORC2). mTOR signaling is often dysregulated in cancers and has been considered an attractive cancer therapeutic target. Great efforts have been made to develop efficacious mTOR inhibitors, particularly mTOR kinase inhibitors, which suppress mTORC1 and mTORC2; however, major success has not been achieved. With the strong scientific rationale, the intriguing question is why cancers are insensitive or not responsive to mTOR-targeted cancer therapy in clinics. Beyond early findings on induced activation of PI3K/Akt, MEK/ERK, and Mnk/eIF4E survival signaling pathways that compromise the efficacy of rapalog-based cancer therapy, recent findings on the essential role of GSK3 in mediating cancer cell response to mTOR inhibitors and mTORC1 inhibition-induced upregulation of PD-L1 in cancer cells may provide some explanations. These new findings may also offer us the opportunity to rationally utilize mTOR inhibitors in cancer therapy. Further elucidation of the biology of complicated mTOR networks may bring us the hope to develop effective therapeutic strategies with mTOR inhibitors against cancer.
W Cai, Q Ye, QB She. Loss of 4E-BP1 function induces EMT and promotes cancer cell migration and invasion via cap-dependent translational activation of snail. Oncotarget 2014; 5(15): 6015–6027 https://doi.org/10.18632/oncotarget.2109
pmid: 24970798
5
DA Guertin, DM Stevens, M Saitoh, S Kinkel, K Crosby, JH Sheen, DJ Mullholland, MA Magnuson, H Wu, DM Sabatini. mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice. Cancer Cell 2009; 15(2): 148–159 https://doi.org/10.1016/j.ccr.2008.12.017
pmid: 19185849
6
K Lee, KT Nam, SH Cho, P Gudapati, Y Hwang, DS Park, R Potter, J Chen, E Volanakis, M Boothby. Vital roles of mTOR complex 2 in Notch-driven thymocyte differentiation and leukemia. J Exp Med 2012; 209(4): 713–728 https://doi.org/10.1084/jem.20111470
pmid: 22473959
7
D Roulin, Y Cerantola, A Dormond-Meuwly, N Demartines, O Dormond. Targeting mTORC2 inhibits colon cancer cell proliferation in vitro and tumor formation in vivo. Mol Cancer 2010; 9(1): 57 https://doi.org/10.1186/1476-4598-9-57
pmid: 20226010
RT Abraham, JJ Gibbons. The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy. Clin Cancer Res 2007; 13(11): 3109–3114 https://doi.org/10.1158/1078-0432.CCR-06-2798
pmid: 17545512
VS Rodrik-Outmezguine, M Okaniwa, Z Yao, CJ Novotny, C McWhirter, A Banaji, H Won, W Wong, M Berger, E de Stanchina, DG Barratt, S Cosulich, T Klinowska, N Rosen, KM Shokat. Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor. Nature 2016; 534(7606): 272–276 https://doi.org/10.1038/nature17963
pmid: 27279227
14
SY Sun, LM Rosenberg, X Wang, Z Zhou, P Yue, H Fu, FR Khuri. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res 2005; 65(16): 7052–7058 https://doi.org/10.1158/0008-5472.CAN-05-0917
pmid: 16103051
15
KE O’Reilly, F Rojo, QB She, D Solit, GB Mills, D Smith, H Lane, F Hofmann, DJ Hicklin, DL Ludwig, J Baselga, N Rosen. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006; 66(3): 1500–1508 https://doi.org/10.1158/0008-5472.CAN-05-2925
pmid: 16452206
16
Y Shi, H Yan, P Frost, J Gera, A Lichtenstein. Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade. Mol Cancer Ther 2005; 4(10): 1533–1540 https://doi.org/10.1158/1535-7163.MCT-05-0068
pmid: 16227402
17
X Wan, B Harkavy, N Shen, P Grohar, LJ Helman. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 2007; 26(13): 1932–1940 https://doi.org/10.1038/sj.onc.1209990
pmid: 17001314
18
X Wang, P Yue, YA Kim, H Fu, FR Khuri, SY Sun. Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR/raptor inhibition-initiated, mTOR/rictor-independent Akt activation. Cancer Res 2008; 68(18): 7409–7418 https://doi.org/10.1158/0008-5472.CAN-08-1522
pmid: 18794129
19
I Duran, J Kortmansky, D Singh, H Hirte, W Kocha, G Goss, L Le, A Oza, T Nicklee, J Ho, D Birle, GR Pond, D Arboine, J Dancey, S Aviel-Ronen, MS Tsao, D Hedley, LL Siu. A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br J Cancer 2006; 95(9): 1148–1154 https://doi.org/10.1038/sj.bjc.6603419
pmid: 17031397
20
J Tabernero, F Rojo, E Calvo, H Burris, I Judson, K Hazell, E Martinelli, S Ramon y Cajal, S Jones, L Vidal, N Shand, T Macarulla, FJ Ramos, S Dimitrijevic, U Zoellner, P Tang, M Stumm, HA Lane, D Lebwohl, J Baselga. Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol 2008; 26(10): 1603–1610 https://doi.org/10.1200/JCO.2007.14.5482
pmid: 18332469
Y Li, X Wang, P Yue, H Tao, SS Ramalingam, TK Owonikoko, X Deng, Y Wang, H Fu, FR Khuri, SY Sun. Protein phosphatase 2A and DNA-dependent protein kinase are involved in mediating rapamycin-induced Akt phosphorylation. J Biol Chem 2013; 288(19): 13215–13224 https://doi.org/10.1074/jbc.M113.463679
pmid: 23536185
24
A Carracedo, L Ma, J Teruya-Feldstein, F Rojo, L Salmena, A Alimonti, A Egia, AT Sasaki, G Thomas, SC Kozma, A Papa, C Nardella, LC Cantley, J Baselga, PP Pandolfi. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 2008; 118(9): 3065–3074 https://doi.org/10.1172/JCI34739
pmid: 18725988
25
X Wang, N Hawk, P Yue, J Kauh, SS Ramalingam, H Fu, FR Khuri, SY Sun. Overcoming mTOR inhibition-induced paradoxical activation of survival signaling pathways enhances mTOR inhibitors’ anticancer efficacy. Cancer Biol Ther 2008; 7(12): 1952–1958 https://doi.org/10.4161/cbt.7.12.6944
pmid: 18981735
26
X Wang, P Yue, CB Chan, K Ye, T Ueda, R Watanabe-Fukunaga, R Fukunaga, H Fu, FR Khuri, SY Sun. Inhibition of mammalian target of rapamycin induces phosphatidylinositol 3 kinase-dependent and Mnk-mediated eIF4E phosphorylation. Mol Cell Biol 2007; 27(21): 7405–7413 https://doi.org/10.1128/MCB.00760-07
CN Mills, S Nowsheen, JA Bonner, ES Yang. Emerging roles of glycogen synthase kinase 3 in the treatment of brain tumors. Front Mol Neurosci 2011; 4: 47 https://doi.org/10.3389/fnmol.2011.00047
pmid: 22275880
JA McCubrey, NM Davis, SL Abrams, G Montalto, M Cervello, J Basecke, M Libra, F Nicoletti, L Cocco, AM Martelli, LS Steelman. Diverse roles of GSK-3: tumor promoter-tumor suppressor, target in cancer therapy. Adv Biol Regul 2014; 54: 176–196 https://doi.org/10.1016/j.jbior.2013.09.013
pmid: 24169510
32
M Medina, F Wandosell. Deconstructing GSK-3: the fine regulation of its activity. Int J Alzheimers Dis 2011; 2011: 479249 https://doi.org/10.4061/2011/479249
pmid: 21629747
33
S Shin, L Wolgamott, Y Yu, J Blenis, SO Yoon. Glycogen synthase kinase (GSK)-3 promotes p70 ribosomal protein S6 kinase (p70S6K) activity and cell proliferation. Proc Natl Acad Sci USA 2011; 108(47): E1204–E1213 https://doi.org/10.1073/pnas.1110195108
pmid: 22065737
34
J Koo, X Wang, TK Owonikoko, SS Ramalingam, FR Khuri, SY Sun. GSK3 is required for rapalogs to induce degradation of some oncogenic proteins and to suppress cancer cell growth. Oncotarget 2015; 6(11): 8974–8987 https://doi.org/10.18632/oncotarget.3291
pmid: 25797247
35
J Koo, P Yue, AA Gal, FR Khuri, SY Sun. Maintaining glycogen synthase kinase-3 activity is critical for mTOR kinase inhibitors to inhibit cancer cell growth. Cancer Res 2014; 74(9): 2555–2568 https://doi.org/10.1158/0008-5472.CAN-13-2946
pmid: 24626091
36
S Zhang, G Qian, QQ Zhang, Y Yao, D Wang, ZG Chen, LJ Wang, M Chen, SY Sun. mTORC2 suppresses GSK3-dependent Snail degradation to positively regulate cancer cell invasion and metastasis. Cancer Res 2019; 79(14): 3725–3736 https://doi.org/10.1158/0008-5472.CAN-19-0180
pmid: 31142514
37
K Inoki, H Ouyang, T Zhu, C Lindvall, Y Wang, X Zhang, Q Yang, C Bennett, Y Harada, K Stankunas, CY Wang, X He, OA MacDougald, M You, BO Williams, KL Guan. TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell 2006; 126(5): 955–968 https://doi.org/10.1016/j.cell.2006.06.055
pmid: 16959574
38
HH Zhang, AI Lipovsky, CC Dibble, M Sahin, BD Manning. S6K1 regulates GSK3 under conditions of mTOR-dependent feedback inhibition of Akt. Mol Cell 2006; 24(2): 185–197 https://doi.org/10.1016/j.molcel.2006.09.019
pmid: 17052453
39
J Koo, P Yue, X Deng, FR Khuri, SY Sun. mTOR complex 2 stabilizes Mcl-1 protein by suppressing its GSK3-dependent and SCF-FBXW7-mediated degradation. Mol Cell Biol 2015; 35: 2344–2355 https://doi.org/10.1128/MCB.01525-14
pmid: 25918246
40
S Li, YT Oh, P Yue, FR Khuri, SY Sun. Inhibition of mTOR complex 2 induces GSK3/FBXW7-dependent degradation of sterol regulatory element-binding protein 1 (SREBP1) and suppresses lipogenesis in cancer cells. Oncogene 2016; 35(5): 642–650 https://doi.org/10.1038/onc.2015.123
pmid: 25893295
41
M Welcker, BE Clurman. FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation. Nat Rev Cancer 2008; 8(2): 83–93 https://doi.org/10.1038/nrc2290
pmid: 18094723
42
H Inuzuka, S Shaik, I Onoyama, D Gao, A Tseng, RS Maser, B Zhai, L Wan, A Gutierrez, AW Lau, Y Xiao, AL Christie, J Aster, J Settleman, SP Gygi, AL Kung, T Look, KI Nakayama, RA DePinho, W Wei. SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. Nature 2011; 471(7336): 104–109 https://doi.org/10.1038/nature09732
pmid: 21368833
BP Zhou, J Deng, W Xia, J Xu, YM Li, M Gunduz, MC Hung. Dual regulation of Snail by GSK-3β-mediated phosphorylation in control of epithelial–mesenchymal transition. Nat Cell Biol 2004; 6(10): 931–940 https://doi.org/10.1038/ncb1173
pmid: 15448698
47
DD Sarbassov, SM Ali, S Sengupta, JH Sheen, PP Hsu, AF Bagley, AL Markhard, DM Sabatini. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 2006; 22(2): 159–168 https://doi.org/10.1016/j.molcel.2006.03.029
pmid: 16603397
48
A Barilli, R Visigalli, R Sala, GC Gazzola, A Parolari, E Tremoli, S Bonomini, A Simon, EI Closs, V Dall’Asta, O Bussolati. In human endothelial cells rapamycin causes mTORC2 inhibition and impairs cell viability and function. Cardiovasc Res 2008; 78(3): 563–571 https://doi.org/10.1093/cvr/cvn024
pmid: 18250144
49
M Rosner, M Hengstschläger. Cytoplasmic and nuclear distribution of the protein complexes mTORC1 and mTORC2: rapamycin triggers dephosphorylation and delocalization of the mTORC2 components rictor and sin1. Hum Mol Genet 2008; 17(19): 2934–2948 https://doi.org/10.1093/hmg/ddn192
pmid: 18614546
50
A Barquilla, JL Crespo, M Navarro. Rapamycin inhibits trypanosome cell growth by preventing TOR complex 2 formation. Proc Natl Acad Sci USA 2008; 105(38): 14579–14584 https://doi.org/10.1073/pnas.0802668105
pmid: 18796613
51
AD Barlow, J Xie, CE Moore, SC Campbell, JA Shaw, ML Nicholson, TP Herbert. Rapamycin toxicity in MIN6 cells and rat and human islets is mediated by the inhibition of mTOR complex 2 (mTORC2). Diabetologia 2012; 55(5): 1355–1365 https://doi.org/10.1007/s00125-012-2475-7
pmid: 22314813
52
DW Lamming, L Ye, P Katajisto, MD Goncalves, M Saitoh, DM Stevens, JG Davis, AB Salmon, A Richardson, RS Ahima, DA Guertin, DM Sabatini, JA Baur. Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. Science 2012; 335(6076): 1638–1643 https://doi.org/10.1126/science.1215135
pmid: 22461615
53
SM Hong, CW Park, HJ Cha, JH Kwon, YS Yun, NG Lee, DG Kim, HG Nam, KY Choi. Rapamycin inhibits both motility through down-regulation of p-STAT3 (S727) by disrupting the mTORC2 assembly and peritoneal dissemination in sarcomatoid cholangiocarcinoma. Clin Exp Metastasis 2013; 30(2): 177–187 https://doi.org/10.1007/s10585-012-9526-9
pmid: 22875246
54
Q Ding, X He, W Xia, JM Hsu, CT Chen, LY Li, DF Lee, JY Yang, X Xie, JC Liu, MC Hung. Myeloid cell leukemia-1 inversely correlates with glycogen synthase kinase-3β activity and associates with poor prognosis in human breast cancer. Cancer Res 2007; 67(10): 4564–4571 https://doi.org/10.1158/0008-5472.CAN-06-1788
pmid: 17495324
55
R Chung, AC Peters, H Armanious, M Anand, P Gelebart, R Lai. Biological and clinical significance of GSK-3β in mantle cell lymphoma—an immunohistochemical study. Int J Clin Exp Pathol 2010; 3(3): 244–253 PMID:20224723
56
YJ Cho, JH Kim, J Yoon, SJ Cho, YS Ko, JW Park, HS Lee, HE Lee, WH Kim, BL Lee. Constitutive activation of glycogen synthase kinase-3β correlates with better prognosis and cyclin-dependent kinase inhibitors in human gastric cancer. BMC Gastroenterol 2010; 10(1): 91 https://doi.org/10.1186/1471-230X-10-91
pmid: 20704706
57
G Qiao, Y Le, J Li, L Wang, F Shen. Glycogen synthase kinase-3β is associated with the prognosis of hepatocellular carcinoma and may mediate the influence of type 2 diabetes mellitus on hepatocellular carcinoma. PLoS One 2014; 9(8): e105624 https://doi.org/10.1371/journal.pone.0105624
pmid: 25157753
J Guan, KS Lim, T Mekhail, CC Chang. Programmed death ligand-1 (PD-L1) expression in the programmed death receptor-1 (PD-1)/PD-L1 blockade: a key player against various cancers. Arch Pathol Lab Med 2017; 141(6): 851–861 https://doi.org/10.5858/arpa.2016-0361-RA
pmid: 28418281
61
DM Benson Jr, CE Bakan, A Mishra, CC Hofmeister, Y Efebera, B Becknell, RA Baiocchi, J Zhang, J Yu, MK Smith, CN Greenfield, P Porcu, SM Devine, R Rotem-Yehudar, G Lozanski, JC Byrd, MA Caligiuri. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood 2010; 116(13): 2286–2294 https://doi.org/10.1182/blood-2010-02-271874
pmid: 20460501
62
SR Gordon, RL Maute, BW Dulken, G Hutter, BM George, MN McCracken, R Gupta, JM Tsai, R Sinha, D Corey, AM Ring, AJ Connolly, IL Weissman. PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature 2017; 545(7655): 495–499 https://doi.org/10.1038/nature22396
pmid: 28514441
KJ Lastwika, W Wilson 3rd, QK Li, J Norris, H Xu, SR Ghazarian, H Kitagawa, S Kawabata, JM Taube, S Yao, LN Liu, JJ Gills, PA Dennis. Control of PD-L1 expression by oncogenic activation of the AKT-mTOR pathway in non-small cell lung cancer. Cancer Res 2016; 76(2): 227–238 https://doi.org/10.1158/0008-5472.CAN-14-3362
pmid: 26637667
67
L Deng, G Qian, S Zhang, H Zheng, S Fan, GB Lesinski, TK Owonikoko, SS Ramalingam, SY Sun. Inhibition of mTOR complex 1/p70 S6 kinase signaling elevates PD-L1 levels in human cancer cells through enhancing protein stabilization accompanied with enhanced β-TrCP degradation. Oncogene 2019; 38(35): 6270–6282 https://doi.org/10.1038/s41388-019-0877-4
pmid: 31316145
68
Y Hirayama, M Gi, S Yamano, H Tachibana, T Okuno, S Tamada, T Nakatani, H Wanibuchi. Anti-PD-L1 treatment enhances antitumor effect of everolimus in a mouse model of renal cell carcinoma. Cancer Sci 2016; 107(12): 1736–1744 https://doi.org/10.1111/cas.13099
pmid: 27712020
69
C Zhang, Y Duan, M Xia, Y Dong, Y Chen, L Zheng, S Chai, Q Zhang, Z Wei, N Liu, J Wang, C Sun, Z Tang, X Cheng, J Wu, G Wang, F Zheng, A Laurence, B Li, XP Yang. TFEB mediates immune evasion and resistance to mTOR inhibition of renal cell carcinoma via induction of PD-L1. Clin Cancer Res 2019; 25(22): 6827–6838 https://doi.org/10.1158/1078-0432.CCR-19-0733
pmid: 31383732
AM Holder, A Akcakanat, F Adkins, K Evans, H Chen, C Wei, DR Milton, Y Li, KA Do, F Janku, F Meric-Bernstam. Epithelial to mesenchymal transition is associated with rapamycin resistance. Oncotarget 2015; 6(23): 19500–19513 https://doi.org/10.18632/oncotarget.3669
pmid: 25944619
72
S Venkatesan, M Hoogstraat, E Caljouw, T Pierson, JK Spoor, L Zeneyedpour, HJ Dubbink, LJ Dekker, M van der Kaaij, J Kloezeman, LM Berghauser Pont, NJ Besselink, TM Luider, J Joore, JW Martens, ML Lamfers, S Sleijfer, S Leenstra. TP53 mutated glioblastoma stem-like cell cultures are sensitive to dual mTORC1/2 inhibition while resistance in TP53 wild type cultures can be overcome by combined inhibition of mTORC1/2 and Bcl-2. Oncotarget 2016; 7(36): 58435–58444 https://doi.org/10.18632/oncotarget.11205
pmid: 27533080
73
J Tan, Z Li, PL Lee, P Guan, MY Aau, ST Lee, M Feng, CZ Lim, EY Lee, ZN Wee, YC Lim, RK Karuturi, Q Yu. PDK1 signaling toward PLK1-MYC activation confers oncogenic transformation, tumor-initiating cell activation, and resistance to mTOR-targeted therapy. Cancer Discov 2013; 3(10): 1156–1171 https://doi.org/10.1158/2159-8290.CD-12-0595
pmid: 23887393
74
Y Liu, X Zhang, P Liu, J Zhang. Drug sensitivity research of mTOR inhibitor on breast cancer stem cells. Natl Med J China (Zhonghua Yi Xue Za Zhi) 2015; 95(24): 1910–1914 (in Chinese)
pmid: 26710692
75
F Lin, MC de Gooijer, D Hanekamp, G Chandrasekaran, LC Buil, N Thota, RW Sparidans, JH Beijnen, T Würdinger, O van Tellingen. PI3K-mTOR pathway inhibition exhibits efficacy against high-grade glioma in clinically relevant mouse models. Clin Cancer Res 2017; 23(5): 1286–1298 https://doi.org/10.1158/1078-0432.CCR-16-1276
pmid: 27553832
76
J Wang, DH Yang, Y Yang, JQ Wang, CY Cai, ZN Lei, QX Teng, ZX Wu, L Zhao, ZS Chen. Overexpression of ABCB1 transporter confers resistance to mTOR inhibitor WYE-354 in cancer cells. Int J Mol Sci 2020; 21(4): E1387 https://doi.org/10.3390/ijms21041387
pmid: 32092870
77
F Lin, L Buil, D Sherris, JH Beijnen, O van Tellingen. Dual mTORC1 and mTORC2 inhibitor Palomid 529 penetrates the blood-brain barrier without restriction by ABCB1 and ABCG2. Int J Cancer 2013; 133(5): 1222–1233 https://doi.org/10.1002/ijc.28126
pmid: 23436212
78
E Lauretti, O Dincer, D Praticò. Glycogen synthase kinase-3 signaling in Alzheimer’s disease. Biochim Biophys Acta Mol Cell Res 2020; 1867(5): 118664 https://doi.org/10.1016/j.bbamcr.2020.118664
pmid: 32006534
79
P Duda, J Wiśniewski, T Wójtowicz, O Wójcicka, M Jaśkiewicz, D Drulis-Fajdasz, D Rakus, JA McCubrey, A Gizak. Targeting GSK3 signaling as a potential therapy of neurodegenerative diseases and aging. Expert Opin Ther Targets 2018; 22(10): 833–848 https://doi.org/10.1080/14728222.2018.1526925
pmid: 30244615
80
JT Lynch, UM Polanska, U Hancox, O Delpuech, J Maynard, C Trigwell, C Eberlein, C Lenaghan, R Polanski, A Avivar-Valderas, M Cumberbatch, T Klinowska, SE Critchlow, F Cruzalegui, ST Barry. Combined inhibition of PI3Kβ and mTOR inhibits growth of PTEN-null tumors. Mol Cancer Ther 2018; 17(11): 2309–2319 https://doi.org/10.1158/1535-7163.MCT-18-0183
pmid: 30097489
81
H Kim, SJ Lee, IK Lee, SC Min, HH Sung, BC Jeong, J Lee, SH Park. Synergistic effects of combination therapy with AKT and mTOR inhibitors on bladder cancer cells. Int J Mol Sci 2020; 21(8): E2825 https://doi.org/10.3390/ijms21082825
pmid: 32325639
82
M Mazzoletti, F Bortolin, L Brunelli, R Pastorelli, S Di Giandomenico, E Erba, P Ubezio, M Broggini. Combination of PI3K/mTOR inhibitors: antitumor activity and molecular correlates. Cancer Res 2011; 71(13): 4573–4584 https://doi.org/10.1158/0008-5472.CAN-10-4322
pmid: 21602434
83
J Mise, V Dembitz, H Banfic, D Visnjic. Combined inhibition of PI3K and mTOR exerts synergistic antiproliferative effect, but diminishes differentiative properties of rapamycin in acute myeloid leukemia cells. Pathol Oncol Res 2011; 17(3): 645–656 https://doi.org/10.1007/s12253-011-9365-z
pmid: 21336564
84
A Arnold, M Yuan, A Price, L Harris, CG Eberhart, EH Raabe. Synergistic activity of mTORC1/2 kinase and MEK inhibitors suppresses pediatric low-grade glioma tumorigenicity and vascularity. Neuro-oncol 2020; 22(4): 563–574 https://doi.org/10.1093/neuonc/noz230
pmid: 31841591
85
X Liu, J Hu, X Song, K Utpatel, Y Zhang, P Wang, X Lu, J Zhang, M Xu, T Su, L Che, J Wang, M Evert, DF Calvisi, X Chen. Combined treatment with MEK and mTOR inhibitors is effective in in vitro and in vivo models of hepatocellular carcinoma. Cancers (Basel) 2019; 11(7): E930 https://doi.org/10.3390/cancers11070930
pmid: 31277283
86
ML Chadwick, A Lane, D Thomas, AR Smith, AR White, D Davidson, Y Feng, E Boscolo, Y Zheng, DM Adams, A Gupta, A Veillette, LML Chow. Combined mTOR and MEK inhibition is an effective therapy in a novel mouse model for angiosarcoma. Oncotarget 2018; 9(37): 24750–24765 https://doi.org/10.18632/oncotarget.25345
pmid: 29872503
87
NJ Andersen, EB Boguslawski, CY Kuk, CM Chambers, NS Duesbery. Combined inhibition of MEK and mTOR has a synergic effect on angiosarcoma tumorgrafts. Int J Oncol 2015; 47(1): 71–80 https://doi.org/10.3892/ijo.2015.2989
pmid: 25955301
H Chi. Regulation and function of mTOR signalling in T cell fate decisions. Nat Rev Immunol 2012; 12(5): 325–338 https://doi.org/10.1038/nri3198
pmid: 22517423
D Fantus, AW Thomson. Evolving perspectives of mTOR complexes in immunity and transplantation. Am J Transplant 2015; 15(4): 891–902 https://doi.org/10.1111/ajt.13151
pmid: 25737114
92
K Araki, AP Turner, VO Shaffer, S Gangappa, SA Keller, MF Bachmann, CP Larsen, R Ahmed. mTOR regulates memory CD8 T-cell differentiation. Nature 2009; 460(7251): 108–112 https://doi.org/10.1038/nature08155
pmid: 19543266
93
JB Mannick, G Del Giudice, M Lattanzi, NM Valiante, J Praestgaard, B Huang, MA Lonetto, HT Maecker, J Kovarik, S Carson, DJ Glass, LB Klickstein. mTOR inhibition improves immune function in the elderly. Sci Transl Med 2014; 6(268): 268ra179 https://doi.org/10.1126/scitranslmed.3009892
pmid: 25540326
94
L Beziaud, L Mansi, P Ravel, EL Marie-Joseph, C Laheurte, L Rangan, F Bonnefoy, JR Pallandre, L Boullerot, C Gamonet, S Vrecko, L Queiroz, T Maurina, G Mouillet, TN Hon, E Curtit, B Royer, B Gaugler, J Bayry, E Tartour, A Thiery-Vuillemin, X Pivot, C Borg, Y Godet, O Adotévi. Rapalogs efficacy relies on the modulation of antitumor T-cell immunity. Cancer Res 2016; 76(14): 4100–4112 https://doi.org/10.1158/0008-5472.CAN-15-2452
pmid: 27197194
95
E Amiel, B Everts, TC Freitas, IL King, JD Curtis, EL Pearce, EJ Pearce. Inhibition of mechanistic target of rapamycin promotes dendritic cell activation and enhances therapeutic autologous vaccination in mice. J Immunol 2012; 189(5): 2151–2158 https://doi.org/10.4049/jimmunol.1103741
pmid: 22826320
96
DL Thomas, R Doty, V Tosic, J Liu, DM Kranz, G McFadden, AL Macneill, EJ Roy. Myxoma virus combined with rapamycin treatment enhances adoptive T cell therapy for murine melanoma brain tumors. Cancer Immunol Immunother 2011; 60(10): 1461–1472 https://doi.org/10.1007/s00262-011-1045-z
pmid: 21656158
97
M Diken, S Kreiter, F Vascotto, A Selmi, S Attig, J Diekmann, C Huber, Ö Türeci, U Sahin. mTOR inhibition improves antitumor effects of vaccination with antigen-encoding RNA. Cancer Immunol Res 2013; 1(6): 386–392 https://doi.org/10.1158/2326-6066.CIR-13-0046
pmid: 24778131
98
Y Mineharu, N Kamran, PR Lowenstein, MG Castro. Blockade of mTOR signaling via rapamycin combined with immunotherapy augments antiglioma cytotoxic and memory T-cell functions. Mol Cancer Ther 2014; 13(12): 3024–3036 https://doi.org/10.1158/1535-7163.MCT-14-0400
pmid: 25256739
99
EC Moore, HA Cash, AM Caruso, R Uppaluri, JW Hodge, C Van Waes, CT Allen. Enhanced tumor control with combination mTOR and PD-L1 inhibition in syngeneic oral cavity cancers. Cancer Immunol Res 2016; 4(7): 611–620 https://doi.org/10.1158/2326-6066.CIR-15-0252
pmid: 27076449